What I see in all comment in klse group stock , the negatives comment but soon price flying to sky...but prise higher to sky for some stock, price jumping to earth after that...
By now, most of you here would probably know that the company is collaborating with a US company to produce a vaccine for this ongoing pandemic.
What really intrigued me was the company is only funding US$1 million for this vaccine research. Got so cheap or not??
Generally, you and I are no medical professional and know nuts about medical treatment. Nonetheless, personally, I am a curious investor and the only source of info is via online reading materials. And hence, I did abit of my findings. (Thanks to @pBlue for also sharing a site for me to refer)
So the first question is: Can this poliovaccine really work against covid treatment? In short, no proven studies yet, but scientists believe it is plausible. Here are their rationales. 1) Both poliovirus and coronavirus are positive-strand RNA viruses; therefore, it is likely that they may induce and be affected by common innate immunity mechanisms 2) By using Poliovaccine, it would enable one to trigger an immune response to develop antibodies specific to the pathogen, such as the previous virus, SARS-Cov 2. However, they believe is just a temporary immune boost. So the keyword is Temporary. Imagine if we can walk freely for a year without the fear of transmission, ok ma isn’t? 3) Safety. Using existing vaccines is safer due to track record of safety
The next question would be: If poliovaccine is effective, why do people still getting covid 19? To be honest, I can’t find any studies or news but my suspicion was, what if the poliovaccine has a protection period? The only info I found was from a UK healthcare called “Superdrug Health Clinic”. According to them, the vaccine only lasts for 10 years and one should get another after 10 years. I am uncertain about this fact as “Booster” and “Vaccine” may have different usage. However, hypothetically, if one requires another jab after 10 years, that explains why children are less prone as compared to the elderly in regards to contracting the covid 19 virus.
That being said, it is worth noting that this poliovaccine is not the panacea for all of us. It is far too early to conclude as more clinical trials should be done.
But if the company or its US counterpart DID manage to pass its clinical trial or getting FDA approval, it would definitely be good news to all, especially the investors.
In my next piece, I will try to find more info on the company’s credential / track record in relation to healthcare. Stay tuned !
Disclaimer: the write up is for discussion purposes and not inducing any buy/sell call. I hope everyone would discuss sensibly
Already, nearly 1,500 Dutch health care workers have rolled up their sleeves for a study that Netea's team is leading. It uses a TB vaccine named BCG, which is made of a live but weakened bacterial cousin of the TB germ.
In Australia, researchers hope to enroll 4,000 hospital workers to test BCG, too, and 700 already have received either the TB vaccine or a dummy shot. Similar research is being planned in other countries, including the U.S.
Possibly next in line: oral polio vaccine, drops made of live but weakened polio viruses. The Baltimore-based Global Virus Network hopes to begin similar studies with the vaccine and is in talks with health authorities
Ho Wah Genting Bhd (HWGB) today signed a joint venture agreement (JV) with US-based E-Mo Biology Inc (EBI) to undertake Phase 4 clinical trials for a new poliomyelitis virus vaccine (PVV) for Covid-19.
The deal, which signed by HWGB's wholly-owned subsidiary HWGB Biotech Sdn Bhd (HWGB Biotech), will also allow the latter to conduct research and development (R&D) of vaccines, immunological treatment and diagnostic product development for the Covid-19 virus.
Under the JV, HWGB Biotech will invest US$1 million and be entitled to a 40 per cent of the total net profit, HWGB Bursa Malaysia filing today said.
Furthermore, following the memorandum of agreement signed on 06 August 2020, HWGB Biotech will also be entitled to exclusive rights for the production, distribution and the sale of the Covid-19 vaccine in Southeast Asia countries.
"We hope the repurposing of the proven poliovirus vaccines can fast track the Covid-19 vaccine development to save lives, as the situation now is dire," said HWGB chief executive officer Datuk Aaron Lim Ooi Hong.
"Additionally, the JV represents a further step to firm up the collaboration of both parties that will be beneficial for both," he said in the exchange filing.
EBI will carry out the R&D, testing, registration and commercialisation of the 5 provisional patent application and other activities relating to the patents which EBI owns, for the purpose of treating the diseases.
The vaccine is currently awaiting necessary approval from the United States Food and Drug Administration (FDA) to conduct Phase 4 clinical trials.
KUALA LUMPUR (Aug 10): Shares in Ho Wah Genting Bhd (HWGB) jumped 15.83% or 19 sen to RM1.39 in morning trade today after the group said last week that its subsidiary had inked a memorandum of understanding (MoU) to undertake phase-four clinical trials for a poliomyelitis vaccine for Covid-19.
At 10.50am, shares in HWGB were 11.67% or 14 sen higher at RM1.34, valuing the group at RM696.99 million. It saw 47.69 million shares traded, exceeding its 200-day average volume of 7.5 million shares.
According to the group’s filing with Bursa Malaysia last Thursday, its unit HWGB Biotech Sdn Bhd had partnered with US-based E-MO Biology Inc (EBI) for HWGB to invest a sum of US$1 million (RM4.2 million) in EBI, entitling it to 40% of profit from the commercialised vaccine.
HWGB said it will have exclusive rights for the production, distribution and sale of the repurposed vaccine based on the polio vaccine for use in preventing Covid-19 infections in Southeast Asian countries.
“EBI on June 15 submitted the Initial Investigational New Drug application to the United States Food and Drug Administration to conduct phase IV clinical trials for a new indication which proposes the use of the existing poliomyelitis virus vaccine for prevention of Covid-19, which is currently pending approval.
HWGB said the memorandum is not expected to have any immediate material effect on its earnings, net assets, gearing and share capital.
“However, the proposed collaboration is expected to contribute positively to earnings of HWGB upon successful commercialisation of the new indication.
“The board, having taken into consideration all aspects of the memorandum, is of the opinion that the memorandum is in the best interests of the company,” said HWGB
KUALA LUMPUR: Ho Wah Genting Bhd (HWGB) today signed a joint venture agreement (JV) with US-based E-Mo Biology Inc (EBI) to undertake Phase 4 clinical trials for a new poliomyelitis virus vaccine (PVV) for Covid-19.
The deal, which signed by HWGB's wholly-owned subsidiary HWGB Biotech Sdn Bhd (HWGB Biotech), will also allow the latter to conduct research and development (R&D) of vaccines, immunological treatment and diagnostic product development for the Covid-19 virus.
Under the JV, HWGB Biotech will invest US$1 million and be entitled to a 40 per cent of the total net profit, HWGB Bursa Malaysia filing today said.
Furthermore, following the memorandum of agreement signed on 06 August 2020, HWGB Biotech will also be entitled to exclusive rights for the production, distribution and the sale of the Covid-19 vaccine in Southeast Asia countries.
"We hope the repurposing of the proven poliovirus vaccines can fast track the Covid-19 vaccine development to save lives, as the situation now is dire," said HWGB chief executive officer Datuk Aaron Lim Ooi Hong.
"Additionally, the JV represents a further step to firm up the collaboration of both parties that will be beneficial for both," he said in the exchange filing.
EBI will carry out the R&D, testing, registration and commercialisation of the 5 provisional patent application and other activities relating to the patents which EBI owns, for the purpose of treating the diseases.
The vaccine is currently awaiting necessary approval from the United States Food and Drug Administration (FDA) to conduct Phase 4 clinical trials.
To be honest, theres many vaccine being developed and HWGB is just investing in one of them, which might not produce any positive result like the others, worst case they fail the stage 4 trial.
2.2 Information on EBI EBI was incorporated in United States of America on 24 May 2020 with authorized shares of 1,000,000. EBI is principally engaged in biology research and development. The sole director and shareholder of EBI is Qiyi Xie. He is also the Chief Executive Officer of EBI.
Hunter888 I believe in u, another hunterr I read back your comment said waiting approval moh, then after that suddenly news appear, the price is fly high...so I wait for your next good hint ..pls share some hint here ...if u have good news will appear soon....
Hunter888 I believe in u, another hunterr I read back your comment said waiting approval moh, then after that suddenly news appear, the price is fly high...so I wait for your next good hint ..pls share some hint here ...if u have good news will appear soon....
How are we progressing so quickly on the coronavirus vaccine front?
One of the possible reasons is that the SARS-CoV-2 vaccine, which causes COVID-19, is from the family of coronaviruses that scientists have studied before. This meant that they could quickly adapt the vaccine projects in the works for previous coronaviruses like the SARS virus and MERS virus. The spike protein which had been pointed out earlier as a component of the coronaviruses, was identified as a target for the vaccine. “SARS-2 is quite similar to SARS-1, especially in that spike protein. People could take a very educated guess that this is the protein that we need to be going after,” Rama Rao Amara, an immunologist and vaccine researcher at Emory University told Stat News.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Malaika
78 posts
Posted by Malaika > 2020-08-15 15:58 | Report Abuse
What I see in all comment in klse group stock , the negatives comment but soon price flying to sky...but prise higher to sky for some stock, price jumping to earth after that...